Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gynecological Cancer
Nedaplatin exhibited strong antitumor activity in gynecological carcinomas
February 16th, 2006
Nedaplatin exhibited strong antitumor activity in human gynecological carcinomas. According to a study from Japan, "The tetrazolium dye (MTT) assay is useful for predicting chemosensitivity. Using the MTT assay, all in vitro chemosensitivity test was designed for nedaplatin (cis-diammine glycolato platinum; 254-S) and the results were compared with the sensitivity to cisplatin in 137 resected gynecological carcinomas." "The mean tumor inhibition rate [I.R.;%] for nedaplatin was equal or superior to cisplatin in 15 cervical [70.7% vs. 63.9%], 65 ovarian [61.7% vs. 54.8%] and 57 endometrial carcinomas [52.1% vs. 47.7%]. In ovarian carcinomas, the I.R.s...
Source: Women's Health Weekly (2006-02-16)
|
